MedTrace Logo

A Trial of HRS-5817 in Obese Participants

NCT07238647 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-12

No results posted yet for this study

Summary

The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of HRS-5817 in obese participants

Conditions

Interventions

DRUG

HRS-5817

Single dose of HRS-5817/placebo given subcutaneously (dose level 1 )

DRUG

HRS-5817

Single dose of HRS-5817/placebo given subcutaneously (dose level 2 )

DRUG

HRS-5817

Single dose of HRS-5817/placebo given subcutaneously (dose level 3 )

DRUG

HRS-5817

Single dose of HRS-5817/placebo given subcutaneously (dose level 4)

Sponsors & Collaborators

  • Atridia Pty Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-05
Primary Completion
2027-01-30
Completion
2027-01-30

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07238647 on ClinicalTrials.gov